CureVac Netherlands
Pharmaceutical Manufacturing • 
Amsterdam, North Holland, Netherlands • 11-20 Employees
Company overview
| Headquarters | Science Park 106, Amsterdam, North Holland 1098 XG, NL |
| Phone number | +31202374970 |
| Websites | |
| NAICS | 3254 |
| Employees | 11-20 |
| Socials |
Key Contacts at CureVac Netherlands
Marlon Stoeckius
Director Antigen Discovery And Computational Biology
Katka Franke
Senior Director Cancer Antigen Discovery And Validation
Katharina Reiko Schropp
Associate Director Strategy & Program Realization
CureVac Netherlands Email Formats
CureVac Netherlands uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@frametherapeutics.com), used 57.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@frametherapeutics.com | 57.1% |
{first initial}.{last name} | j.doe@frametherapeutics.com | 42.9% |
About CureVac Netherlands
CureVac Netherlands BV is dedicated to transforming the treatment of cancer by directing the immune system towards Frame neoantigens. We are developing cancer immunotherapies, that are designed based on the Frame neoantigens uniquely encoded by the genome of each patient's tumor. CureVac Netherlands is part of CureVac AG: a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA) with the main goal to bring multiple best-in-class mRNA drugs to market. The basic principle is the use of this mRNA molecule as a data carrier for information the body needs to fight various diseases. CureVac AG has more than 900 passionate employees, with its headquarters located in Tübingen, Germany and offices in Amsterdam (NL), Frankfurt (Germany), Ottignies-Louvain-la-Neuve (Belgium) and Boston (USA). As Antigen Discovery and Validation Center, CureVac Netherlands focuses on developing innovative cancer immunotherapies and the design and clinical validation of a first off-the-shelf mRNA vaccine targeting a number of shared cancer antigens. In parallel, the antigen discovery technology will be improved and expanded with the goal to develop a platform that enables the detection of all possible antigens expressed by cancer cells. Such platform will form the basis for off-the-shelf and personalised vaccine design for many different cancer types.
CureVac Netherlands revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $53,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,200,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
CureVac Netherlands has 7 employees across 4 departments.
Departments
Number of employees
Funding Data
CureVac Netherlands has never raised funding before.
United States
Finland
United Kingdom
Frequently asked questions
4.8
40,000 users
